Real‐world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey
International Journal of Urology · 2024
DOI: 10.1111/iju.15497 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Li-Jen Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Astellas Pharma Singapore Pte, Ltd., Singapore. Hauptthemen laut MEDLINE: Quality of Life, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma, Inc. and Seagen Inc, which was acquired by Pfizer in Dec. 2023., Astellas Pharma.
Abstract (Originalsprache)
Objectives
To evaluate demographic and clinical characteristics, treatment patterns, and quality of life in patients with locally advanced or metastatic urothelial carcinoma in Asia.
Methods
Data were drawn from the Adelphi Real World Metastatic Urothelial Carcinoma Disease Specific Programme™, a cross‐sectional survey of medical oncologists/urologists and their adult patients in Saudi Arabia, South Korea, Taiwan, and Turkey. Exploratory patient‐reported outcomes included the EQ‐5D visual analog scale, European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health, and Brief Pain Inventory. Analyses were descriptive.
Results
Overall, 175 physicians reported data for 988 patients. Mean (standard deviation) patient age was 66.3 (10.8) years, 77% were men, and 82% had bladder tumors at diagnosis. Of patients receiving first‐ ( n = 988), second‐ ( n = 290), and third‐line ( n = 87) treatments, 81%, 35%, and 59% received chemotherapy, respectively, and 17%, 63%, and 34% received programmed cell death protein 1/ligand 1 inhibitors, respectively. Patient‐reported ( n = 319) mean (standard deviation) EQ‐5D visual analog scale score was 51.8 (15.6), European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health status score was 44.6 (19.9), and Brief Pain Inventory score was 6.5 (1.9; n = 315).
Conclusion
The most common first‐ and second‐line treatments for locally advanced or metastatic urothelial carcinoma were chemotherapy and programmed cell death protein 1/ligand inhibitors, respectively. At third line, 10% of patients received best supportive care alone, underscoring an unmet need for effective third‐line treatment options. Patients in all regions reported quality‐of‐life impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Affairs, Astellas Pharma Singapore Pte, Ltd., Singapore.
- Biostatistics, Astellas Pharma Global Development, Northbrook, Illinois, USA.
- Adelphi Real World, Bollington, UK.
Förderung
- Astellas Pharma, Inc. and Seagen Inc, which was acquired by Pfizer in Dec. 2023.
- Astellas Pharma
Zitieren
APA
Cheng, L. J., Kim, J., Mukherjee, A., Milloy, N., Unsworth, M., & Ng, D. (2024). Real‐world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey. International Journal of Urology. https://doi.org/10.1111/iju.15497
Vancouver
Cheng LJ, Kim J, Mukherjee A, Milloy N, Unsworth M, Ng D. Real‐world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey. International Journal of Urology. 2024. doi:10.1111/iju.15497
BibTeX
@article{Cheng2024,
author = {Cheng, Li-Jen and Kim, Janet and Mukherjee, Apurba and Milloy, Neil and Unsworth, Mia and Ng, Daniel},
title = {Real‐world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15497}
}
EUVIMED